Sphinx Pharmaceuticals
Executive Summary
Announces resignations of President and CEO Clayton Duncan and Exec VP-R&D Jeff Leighton Aug. 26. Three candidates are under consideration to replace Duncan whose resignation is effective Nov. 30. Leighton' successor will be named after the president is chosen. Sphinx says that the resignations are unrelated to the streamlining announced by the Durham, N.C.-based R&D firm July 15.